XML 112 R75.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings per share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 5 Months Ended 6 Months Ended
Jul. 03, 2021
Jun. 27, 2020
Jul. 03, 2021
Jul. 03, 2021
Jul. 03, 2021
Jun. 27, 2020
Jun. 27, 2020
Numerator:              
Net loss $ (10,780) $ (5,980) $ (12,229) $ 13,748 $ 13,748 $ 4,506 $ 4,506
Net loss attributable to noncontrolling interests 6,654 214 7,062 7,062   672  
Net (loss) income attributable to Bioventus Inc. $ (4,126) $ (5,766) $ (5,167) $ 20,810   $ 5,178  
Denominator:              
Weighted-average shares of Class A common stock outstanding - basic (in shares) 41,805,347   41,802,840 41,802,840      
Weighted-average shares of Class A common stock outstanding - diluted (in shares) 41,805,347 [1]   41,802,840 41,802,840 [1]      
Net loss per share of Class A common stock, basic (in dollars per share) $ (0.10) [1]   $ (0.12) $ (0.12) [1]      
Net loss per share of Class A common stock, diluted (in dollars per share) $ (0.10)   $ (0.12) $ (0.12)      
[1] Per share information for the six months ended July 3, 2021 represents loss per share of Class A common stock and weighted-average shares of Class A common stock outstanding from February 16, 2021 through July 3, 2021, the period following Bioventus Inc.’s initial public offering and related transactions described in Note 1. Organization and Note 7. Earnings per share within the Notes to the Unaudited Condensed Consolidated Financial Statements.